Risk of second primary cancer in oral squamous cell carcinoma.
head and neck cancer
oral cancer
second primary cancer
second primary malignancy
second primary tumor
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
07
10
2019
revised:
06
01
2020
accepted:
28
01
2020
pubmed:
15
2
2020
medline:
22
6
2021
entrez:
15
2
2020
Statut:
ppublish
Résumé
The incidence and survival of oral squamous cell carcinoma (OSCC) patients have increased in recent years. Understanding their long-term survival aspects is essential for optimal treatment and follow-up planning. Almost one in five cancers diagnosed occurs nowadays in individuals with a previous diagnosis of cancer. Patients diagnosed with primary OSCC during 1953-2015 were retrieved from the Finnish Cancer Registry. Both standardized incidence ratios (SIR) and excess absolute risk (EAR) per 1000 person-years at risk (PYR) of second primary cancer (SPC) were calculated relative to the general population. Among 6602 first primary OSCC patients there were 640 (10%) SPCs. The SIR for SPCs was 1.85 (95% CI: 1.71-1.99, P < .001) corresponding to an EAR of 8.78 (95% CI: 7.29-10.26). Health care professionals should be aware of the second primary cancer risk after management of primary OSCC and patients need to be counseled about this phenomenon.
Sections du résumé
BACKGROUND
The incidence and survival of oral squamous cell carcinoma (OSCC) patients have increased in recent years. Understanding their long-term survival aspects is essential for optimal treatment and follow-up planning. Almost one in five cancers diagnosed occurs nowadays in individuals with a previous diagnosis of cancer.
METHODS
Patients diagnosed with primary OSCC during 1953-2015 were retrieved from the Finnish Cancer Registry. Both standardized incidence ratios (SIR) and excess absolute risk (EAR) per 1000 person-years at risk (PYR) of second primary cancer (SPC) were calculated relative to the general population.
RESULTS
Among 6602 first primary OSCC patients there were 640 (10%) SPCs. The SIR for SPCs was 1.85 (95% CI: 1.71-1.99, P < .001) corresponding to an EAR of 8.78 (95% CI: 7.29-10.26).
CONCLUSIONS
Health care professionals should be aware of the second primary cancer risk after management of primary OSCC and patients need to be counseled about this phenomenon.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1848-1858Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010;31:100-110.
Olaleye O, Ekrikpo U, Lyne O, Wiseberg J. Incidence and survival trends of lip, intra-oral cavity and tongue base cancers in south-East England. Ann R Coll Surg Engl. 2015;97:229-234.
Ali H, Sinnott SJ, Corcoran P, Deady S, Sharp L, Kabir Z. Oral cancer incidence and survival rates in the Republic of Ireland, 1994-2009. BMC Cancer. 2016;16:950-016.
Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309-316.
Dhanuthai K, Rojanawatsirivej S, Thosaporn W, et al. Oral cancer: A multicenter study. Med Oral Patol Oral Cir Bucal. 2018;23:e23-e29.
Franceschi S, Bidoli E, Herrero R, Munoz N. Comparison of cancers of the oral cavity and pharynx worldwide: etiological clues. Oral Oncol. 2000;36:106-115.
Coelho KR. Challenges of the oral cancer burden in India. J Cancer Epidemiol. 2012;2012:701932.
Mroueh R, Haapaniemi A, Grenman R, et al. Improved outcomes with oral tongue squamous cell carcinoma in Finland. Head Neck. 2017;39:1306-1312.
Warren S. Multiple primary malignant tumors. A survey of the literature and a statistical study. Am J Cancer. 1932;16:1358-1414.
SEER Program Code Manual. 3rd ed. National Cancer Institute: Bethesda (MD); 1998.
Billroth T. Die allgemeine chirurgische Pathologie und Therapie in 51. Georg Reimer, Germany: Vorlesungen-Ein Handbuch fur Studierende and Artze; 1889.
Morton LM, Onel K, Curtis RE, Hungate EA, Armstrong GT. The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults. Am Soc Clin Oncol Educ Book. 2014;34:e57-e67.
Parry C, Kent EE, Mariotto AB, Alfano CM, Rowland JH. Cancer survivors: a booming population. Cancer Epidemiol Biomark Prev. 2011;20:1996-2005.
Haughey BH, Gates GA, Arfken CL, Harvey J. Meta-analysis of second malignant tumors in head and neck cancer: the case for an endoscopic screening protocol. Ann Otol Rhinol Laryngol. 1992;101:105-112.
Hu Q, Wu T, Chen X, et al. The poor outcome of second primary oral squamous cell carcinoma is attributed to Bmi1 upregulation. Cancer Med. 2018;7:1056-1069.
Gal TJ, Huang WY, Chen C, Hayes RB, Schwartz SM. DNA repair gene polymorphisms and risk of second primary neoplasms and mortality in oral cancer patients. Laryngoscope. 2005;115:2221-2231.
Hashibe M, Ritz B, Le AD, Li G, Sankaranarayanan R, Zhang ZF. Radiotherapy for oral cancer as a risk factor for second primary cancers. Cancer Lett. 2005;220:185-195.
Chen SW, Zhang Q, Guo ZM, et al. Trends in clinical features and survival of oral cavity cancer: fifty years of experience with 3,362 consecutive cases from a single institution. Cancer Manag Res. 2018;10:4523-4535.
Ong TK, Murphy C, Smith AB, Kanatas AN, Mitchell DA. Survival after surgery for oral cancer: a 30-year experience. Br J Oral Maxillofac Surg. 2017;55:911-916.
Brierley J, Gospodarowicz M, Wittekind C, eds. TNM classification of malignant tumours. 8th edition ed. USA: Wiley-Blackwell; 2017.
Leinonen MK, Miettinen J, Heikkinen S, Pitkaniemi J, Malila N. Quality measures of the population-based Finnish cancer registry indicate sound data quality for solid malignant tumours. Eur J Cancer. 2017;77:31-39.
Schoenberg BS, Myers MH. Statistical methods for studying multiple primary malignant neoplasms. Cancer. 1977;40:1892-1898.
Official Statistics of Finland (OSF): Population structure [e-publication]. ISSN=1797-5395. Helsinki: Statistics Finland [referred: 10.6.2019]. Access method: http://www.stat.fi/til/vaerak/index_en.html.
Mehanna H, Paleri V, West CM, Nutting C. Head and neck cancer-part 1: epidemiology, presentation, and preservation. Clin Otolaryngol. 2011;36:65-68.
Perry BJ, Zammit AP, Lewandowski AW, et al. Sites of origin of oral cavity cancer in nonsmokers vs smokers: possible evidence of dental trauma carcinogenesis and its importance compared with human papillomavirus. JAMA Otolaryngol Head Neck Surg. 2015;141:5-11.
Xu J, Yang XX, Wu YG, Li XY, Bai B. Meat consumption and risk of oral cavity and oropharynx cancer: a meta-analysis of observational studies. PLoS ONE. 2014;9:e95048.
Rennemo E, Zatterstrom U, Boysen M. Synchronous second primary tumors in 2,016 head and neck cancer patients: role of symptom-directed panendoscopy. Laryngoscope. 2011;121:304-309.
Adjei Boakye E, Buchanan P, Hinyard L, Osazuwa-Peters N, Schootman M, Piccirillo JF. Incidence and risk of second primary malignant neoplasm after a first head and neck squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2018;144:727-737.
Erkal HS, Mendenhall WM, Amdur RJ, Villaret DB, Stringer SP. Synchronous and metachronous squamous cell carcinomas of the head and neck mucosal sites. J Clin Oncol. 2001;19:1358-1362.
Jones AS, Morar P, Phillips DE, Field JK, Husband D, Helliwell TR. Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer. 1995;75:1343-1353.
Bradford PT, Freedman DM, Goldstein AM, Tucker MA. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol. 2010;146:265-272.
Murakami R, Hiyama T, Hanai A, Fujimoto I. Second primary cancers following female breast cancer in Osaka, Japan-a population-based cohort study. Jpn J Clin Oncol. 1987;17:293-302.
Ikeda Y, Saku M, Kawanaka H, Nonaka M, Yoshida K. Features of second primary cancer in patients with gastric cancer. Oncology. 2003;65:113-117.
Morris LG, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol. 2011;29:739-746.
Day GL, Blot WJ. Second primary tumors in patients with oral cancer. Cancer. 1992;70:14-19.
Chuang SC, Scelo G, Tonita JM, et al. Risk of second primary cancer among patients with head and neck cancers: a pooled analysis of 13 cancer registries. Int J Cancer. 2008;123:2390-2396.
Min SK, Choi SW, Lim J, Park JY, Jung KW, Won YJ. Second primary cancers in patients with oral cavity cancer included in the Korea central cancer registry. Oral Oncol. 2019;95:16-28.
Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. BMC Cancer. 2011;11:83-2407.
de Vries N, Van der Waal I, Snow GB. Multiple primary tumours in oral cancer. Int J Oral Maxillofac Surg. 1986;15:85-87.
Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32:605-644.
Leon X, del Prado Venegas M, Orus C, Lopez M, Garcia J, Quer M. Influence of the persistence of tobacco and alcohol use in the appearance of second neoplasm in patients with a head and neck cancer. A case-control study. Cancer Causes Control. 2009;20:645-652.
Yong ZW, Zaini ZM, Kallarakkal TG, et al. Genetic alterations of chromosome 8 genes in oral cancer. Sci Rep. 2014;4:6073.
Kohler LH, Mireskandari M, Knosel T, et al. FGFR1 expression and gene copy numbers in human lung cancer. Virchows Arch. 2012;461:49-57.
von Massenhausen A, Franzen A, Heasley L, Perner S. FGFR1 as a novel prognostic and predictive biomarker in squamous cell cancers of the lung and the head and neck area. Ann Transl Med. 2013;1:23.
Michmerhuizen NL, Birkeland AC, Bradford CR, Brenner JC. Genetic determinants in head and neck squamous cell carcinoma and their influence on global personalized medicine. Genes Cancer. 2016;7:182-200.
Wu LC, Kleinerman RA, Curtis RE, Savage SA, de Gonzalez AB. Patterns of bone sarcomas as a second malignancy in relation to radiotherapy in adulthood and histologic type. Cancer Epidemiol Biomark Prev. 2012;21:1993-1999.
Kontio R, Hagstrom J, Lindholm P, et al. Craniomaxillofacial osteosarcoma - the role of surgical margins. J Craniomaxillofac Surg. 2019;47:922-925.
Tucker MA, D'Angio GJ, Boice JD, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med. 1987;317:588-593.
Travis LB, Andersson M, Gospodarowicz M, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst. 2000;92:1165-1171.
Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med. 1999;340:351-357.
Geurts TW, Nederlof PM, van den Brekel MW, et al. Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary? Clin Cancer Res. 2005;11:6608-6614.
Simple M, Suresh A, Das D, Kuriakose MA. Cancer stem cells and field cancerization of oral squamous cell carcinoma. Oral Oncol. 2015;51:643-651.
Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6:963-968.